Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 13/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.38 |
| ▸ | PDE8A | O60658 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7971739 | 0.81 | SLC29A1 (0.60) | SLC29A1LMNAMEN1KMT2AATM | |
| SCHEMBL7949410 | 0.77 | SLC29A1 (0.63) | SLC29A1LMNAMEN1KMT2AATM | |
| SCHEMBL7976583 | 0.76 | SLC29A1 (0.71) | SLC29A1LMNAMEN1KMT2AATM | |
| SCHEMBL7970119 | 0.76 | SLC29A1 (0.66) | SLC29A1LMNAMEN1KMT2AATM | |
| SCHEMBL7948817 | 0.75 | SLC29A1 (0.57) | SLC29A1LMNAMEN1KMT2AATM | |
| SCHEMBL7971382 | 0.73 | HTT (0.60) | SLC29A1LMNAMEN1KMT2AATM | |
| SCHEMBL7947717 | 0.70 | SLC29A1 (0.86) | SLC29A1LMNAMEN1KMT2AATM | |
| SCHEMBL7960351 | 0.70 | SLC29A1 (0.61) | SLC29A1LMNAMEN1KMT2AATM | |
| SCHEMBL7953158 | 0.69 | SLC29A1 (0.74) | SLC29A1LMNAMEN1KMT2AATM | |
| SCHEMBL7973587 | 0.69 | SLC29A1 (0.53) | SLC29A1LMNAMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2279742-A2 | Combinations for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20090005358-A1 | Compositions and methods for treating medical conditions | LG CHEM, LTD. (KR) | 2009-01-01 | — | — | US | claimed |
| WO-2009002507-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-12-31 | — | — | WO | claimed |
| EP-1999626-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH | CombinatoRx, Incorporated (US) | 2008-12-10 | — | — | EP | claimed |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | COMBINATORX, INCORPORATED | 2008-01-31 | — | — | US | claimed |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | COMBINATORX, INC. | 2008-01-03 | — | — | US | claimed |
| EP-1680121-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2007146012-A1 | TREATMENT OF PERIODONTAL DISEASE ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN LEVELS | COMBINATORX, INCORPORATED (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2007089617-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH | COMBINATORX, INCORPORATED (US) | 2007-08-09 | — | — | WO | claimed |
| JP-2007508391-A | — | — | 2007-04-05 | — | — | JP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| EP-1448205-A4 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1680121-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | claimed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1448205-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003030823-A2 | COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2003-04-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005358-A1 | Compositions and methods for treating medical conditions | ITCH, TSLP, P2RX5 | SLC29A1 2433/4885LMNA 3341/4885MEN1 2256/4885 |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | SLC29A1 1552/4885LMNA 3888/4885MEN1 4127/4885 |
| US-20080025965-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels | TYMP, TTR, TPMT | SLC29A1 908/4885LMNA 3002/4885MEN1 4803/4885 |
| US-20030119786-A1 | Combinations for the treatment of immunoinflammatory disorders | IL5, TSLP, TPMT | SLC29A1 1069/4885LMNA 4264/4885MEN1 3092/4885 |
| US-20080003213-A1 | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels | IFNG, IL6, IL36G | SLC29A1 871/4885LMNA 4193/4885MEN1 4823/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | SLC29A1 1552/4885LMNA 3888/4885MEN1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.